BioRestorative Therapies develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company’s lead cell therapy candidate, brtxDISC™, is formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow intend for use in the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The company is also developing an allogeneic cell-based therapy to target obesity and metabolic disorders. For more information, visit the company’s website at www.biorestorative.com.